Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): 2025 Update on Diagnosis, Pathophysiology, Risk Assessment, and Management

IF 10.1 1区医学 Q1 HEMATOLOGY

American Journal of Hematology Pub Date : 2025-06-17 DOI:10.1002/ajh.27737

Shai Shimony, Marlise R. Luskin, Naseema Gangat, Nicole R. LeBoeuf, Angela M. Feraco, Andrew A. Lane

引用次数: 0

Abstract

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic neoplasm that involves multiple organs, including the skin, bone marrow and blood, lymph nodes, and central nervous system. Violaceous tumors or plaques appearing in sun-exposed areas are characteristic and present in most patients. The disease typically affects adult men aged 60–70 years, although children and younger adults may also be affected.

Abstract Image

查看原文本刊更多论文

母浆细胞样树突状细胞肿瘤（BPDCN）： 2025年诊断、病理生理学、风险评估和管理的最新进展

母浆细胞样树突状细胞肿瘤（BPDCN）是一种罕见的侵袭性血液肿瘤，累及多器官，包括皮肤、骨髓、血液、淋巴结和中枢神经系统。出现在阳光照射区域的紫色肿瘤或斑块是大多数患者的特征性表现。这种疾病通常影响60-70岁的成年男性，尽管儿童和年轻人也可能受到影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American Journal of Hematology 医学-血液学

CiteScore

15.70

自引率

3.90%

发文量

363

审稿时长

3-6 weeks

期刊介绍： The American Journal of Hematology offers extensive coverage of experimental and clinical aspects of blood diseases in humans and animal models. The journal publishes original contributions in both non-malignant and malignant hematological diseases, encompassing clinical and basic studies in areas such as hemostasis, thrombosis, immunology, blood banking, and stem cell biology. Clinical translational reports highlighting innovative therapeutic approaches for the diagnosis and treatment of hematological diseases are actively encouraged.The American Journal of Hematology features regular original laboratory and clinical research articles, brief research reports, critical reviews, images in hematology, as well as letters and correspondence.